Abogen Biosciences Receives Clinical Approval in UAE for Omicron-Specific mRNA COVID-19 Vaccine

Recently, Abogen's Omicron variant strain of the COVID-19 mRNA vaccine received clinical approval in the UAE. Targeting the Omicron strain, Abogen initiated the development of the mRNA vaccine at the end of November 2021 and completed the process from mRNA sequence design to obtaining preliminary immunogenicity data in mice within just 32 days. In addition to the UAE, Abogen is currently actively communicating with regulatory agencies in multiple countries worldwide, including China, with the aim of initiating corresponding clinical trials as soon as possible in accordance with regulatory requirements. In June 2020, the COVID-19 mRNA vaccine jointly developed by Abogen Biosciences, the Academy of Military Medical Sciences, and Walvax Biotechnology was officially approved for clinical trials by the National Medical Products Administration, becoming the first mRNA vaccine in China to be approved for clinical trials. This vaccine is currently in Phase III clinical trials. The company obtained the "Drug Production License" for its COVID-19 mRNA vaccine in November 2021.

Source: 21st Century Economic Report